Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sparsentan - Travere Therapeutics

Drug Profile

Sparsentan - Travere Therapeutics

Alternative Names: DARA; FILSPARI; PS-433540; RE-021

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin; Travere Therapeutics
  • Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy; Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed IgA nephropathy
  • Phase III Focal segmental glomerulosclerosis
  • Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
  • Discontinued Hypertension

Most Recent Events

  • 13 Mar 2024 Travere Therapeutics expects to receive notice for sNDA acceptance for review from the FDA for sparsentan in IgA nephropathy in second quarter of 2024
  • 11 Mar 2024 Travera Therapeutics submits sNDA for conversion of existing accelerated approval to full approval to US FDA for IgA nephropathy
  • 27 Feb 2024 Travere therapeutics and CSL Vifor expects a European Commission decision for approval of conditional marketing authorisation for IgA nephropathy by Q2 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top